|
Market Closed -
Other stock markets
|
Pre-market 13:11:41 | |||
| 320.84 USD | -0.57% |
|
322.72 | +0.58% |
| Capitalization | 35.5B 30.21B 28.2B 26.46B 48.92B 3,202B 53.26B 329B 128B 1,513B 133B 130B 5,512B | P/E ratio 2025 * |
103x | P/E ratio 2026 * | 47.8x |
|---|---|---|---|---|---|
| Enterprise value | 33.17B 28.22B 26.34B 24.72B 45.7B 2,991B 49.75B 307B 119B 1,413B 124B 122B 5,149B | EV / Sales 2025 * |
6.28x | EV / Sales 2026 * | 5.07x |
| Free-Float |
96.17% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BeOne Medicines AG
| 1 day | +0.58% | ||
| 1 week | -3.19% | ||
| Current month | -5.80% | ||
| 1 month | -6.64% | ||
| 3 months | -4.42% | ||
| 6 months | +22.27% | ||
| Current year | +73.70% |
| 1 week | 315.5 |  | 331.83 |
| 1 month | 310.11 | | 385.22 |
| Current year | 172.67 | | 385.22 |
| 1 year | 170.99 | | 385.22 |
| 3 years | 126.97 | | 385.22 |
| 5 years | 118.18 | | 426.56 |
| 10 years | 22.51 | | 426.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Oyler
CEO | Chief Executive Officer | 56 | 27/10/2010 |
Xiao Bin Wu
PSD | President | 63 | 31/03/2018 |
Aaron Rosenberg
DFI | Director of Finance/CFO | 49 | 21/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
John Oyler
CHM | Chairman | 56 | 26/01/2016 |
Michael Goller
BRD | Director/Board Member | 50 | 31/03/2015 |
Ranjeev Krishana
BRD | Director/Board Member | 51 | 30/09/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.57% | -3.19% | +74.01% | +62.86% | 35.5B | |
| -1.41% | -4.75% | -5.62% | +11.65% | 46.35B | |
| +1.37% | +0.47% | +12.39% | +8.37% | 38.48B | |
| +0.54% | +2.25% | +10.68% | +17.47% | 27.77B | |
| +0.96% | +3.92% | +65.78% | +175.14% | 15.95B | |
| +0.81% | +0.04% | +69.09% | +230.15% | 15.18B | |
| +2.19% | +2.24% | -10.49% | -2.48% | 14.5B | |
| -1.61% | -3.24% | +71.01% | - | 13.14B | |
| +0.65% | -3.26% | +108.32% | +111.04% | 12.82B | |
| +4.43% | +0.76% | +56.51% | +79.52% | 12.84B | |
| Average | +0.86% | -0.48% | +45.17% | +77.08% | 23.25B | |
| Weighted average by Cap. | +0.42% | -0.98% | +34.98% | +55.94% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5.28B 4.5B 4.2B 3.94B 7.28B 477B 7.93B 48.91B 19B 225B 19.83B 19.41B 821B | 6.41B 5.46B 5.09B 4.78B 8.84B 578B 9.62B 59.34B 23.06B 273B 24.06B 23.55B 995B |
| Net income | 319M 272M 254M 238M 440M 28.8B 479M 2.95B 1.15B 13.6B 1.2B 1.17B 49.57B | 700M 595M 556M 521M 964M 63.11B 1.05B 6.48B 2.52B 29.81B 2.63B 2.57B 109B |
| Net Debt | -2.34B -1.99B -1.86B -1.74B -3.22B -211B -3.51B -21.64B -8.41B -99.64B -8.78B -8.59B -363B | -2.99B -2.54B -2.37B -2.23B -4.11B -269B -4.48B -27.64B -10.74B -127B -11.21B -10.97B -464B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/12/25 | 320.84 $ | -0.57% | 189,917 |
| 10/12/25 | 322.68 $ | +1.25% | 140,591 |
| 09/12/25 | 318.69 $ | -2.39% | 307,395 |
| 08/12/25 | 326.49 $ | +1.11% | 259,795 |
| 05/12/25 | 322.90 $ | -2.56% | 603,844 |
Delayed Quote Nasdaq, December 11, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ONC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition